Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...